Haemophilia: open trials in Sweden

8 open trials have a site in Sweden. Registry data; only the trial team decides who can take part.

2025-523660-21-00
A Non-Investigational Product, Multi-Center Cohort Study to Describe Long-Term Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec
Trial Treatment · Phase 3 · Pfizer Inc.
Skåne University Hospital, Department of Hematology, Oncology and Radiation Physics, Malmö
Registry updated 2026-10-23
NCT05568719
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
Trial Treatment · Phase 3 · Pfizer
Skåne University Hospital, Malmö
Registry updated 2026-10-07
NCT04023019
Treatment of Hemophilia A Patients With FVIII Inhibitors
Research · Phase 4 · Emory University
Region Skane Skanes Universitetssjukhus, Malmo
Registry updated 2026-09-23
NCT07220564
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
Trial Treatment · Phase 1 · Novo Nordisk A/S
Region Skane Skanes Universitetssjukhus, Malmo · Karolinska University Hospital, Solna
Registry updated 2026-09-18
NCT02979119
The European Paediatric Network for Haemophilia Management ( PedNet Registry)
Research · PedNet Haemophilia Research Foundation
Lund University Hospital, Malmö · Department of Pediatrics, Clinic of Coag. Disorders Karolinska Hospital, Stockholm
Registry updated 2025-09-16
NCT02453542
Global Haemostatic Methods Following Administration of Bypassing Agents to Patients With Haemophilia With Inhibitors
Research · Karolinska Institutet
Karolinska University Hospital, Solna
Registry updated 2025-09-02
NCT05962398
Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)
Research · Phase 2/3 · CSL Behring
Region Skane Skanes Universitetssjukhus, Malmo
Registry updated 2025-07-18
2022-502030-12-01
This is a first in human study, in patients with severe bleeding disorder (hemophilia A), who has developed inhibitory antibodies against coagulation factor VIII.The aim is to study the safety and efficacy of dendritic cells, originating from the patient itself. The dendritic cells has been loaded with coagulation factor VIII for an improved immunological tolerance. (TOLER8)
Trial Treatment · Phase 1 · Cell4Cure AB
Lund University Hospital, Lund
Registry updated 2025-03-24

All Haemophilia trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error